ClinicalTrials.gg
Active, not recruitingNCT05168085Updated Aug 24, 2023

Efficacy of Providing Eggs as an Early Complementary Food to Promote Child Growth

An interventional study of Eggs in Linear Growth, sponsored by North-West University, South Africa. Active, not recruiting at 1 site in South Africa. Open to participants aged 6 Months to 9 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by North-West University, South Africa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
655
Allocation
Randomized
Ages
6 Months to 9 Months
Sex
All
01

Study summary

This study will investigate the efficacy of providing one chicken egg per day for a period of 6 months, beginning at the age of 6 to \<9 months on the growth, motor development, micronutrient, and morbidity status of infants from a low socioeconomic community in South Africa.

Read the detailed description

The nutritional benefit of eggs, in particular chicken eggs is well documented. However, there is paucity of evidence regarding including eggs, in particular chicken eggs during the early complementary feeding phase to enhance child growth and development. Thus, this study seeks to determine and to provide evidence on the effectiveness of including chicken eggs as an early complementary food to enhance early child growth and development. This randomised controlled trial will contribute towards building a strong evidence for the promotion and use of eggs as a healthy and nutritious early complementary food, and can be used to inform future programming regarding infant and young child feeding in low- and middle-income countries.

This is a randomised controlled trial with a parallel design (2 groups). Five hundred infants aged 6 to \<9 months will be included. Infants with egg allergy or sensitization will be excluded. Data will be collected in three months' interval for six months. At baseline, body measurements of mother and infant will be taken; infant's dietary intake using 24-hour recall methods; breastfeeding and complementary feeding practices; infant and maternal allergy and maternal depression with structured questionnaires. Morbidity symptoms and compliance will be recorded daily and followed up weekly. Developmental milestones will be assessed weekly using Pictorial Gross Motor Milestone Chart. Household food security will be assessed. Capillary blood will be collected by means of finger and/or heal prick. This will be a community driven project. Data will be analysed according to intention to treat.

02

Conditions studied

  • Linear Growth
03

In context

Lead sponsor

North-West University, South Africa is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 9 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident in the study municipality; Infants aged 6 to \<9 months

Exclusion criteria

Exclusion Criteria:

  • Severe obvious congenital abnormalities such as cleft lip and spina bifida; Severe anaemia ( \<70 g/L); Severe acute malnutrition (weight-for-length z-score \< -3); Plans to move out of the study area in the next nine months; Known allergies/intolerances to eggs; Infants receiving special nutritional supplements as part of feeding programmes; Not been born as a singleton; Mother/legal guardian below 18 years old at the start of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
655 participants (actual)

Study arms

  • Experimental
    Intervention group

    One chicken egg per day

    Dietary Supplement: Eggs

  • No intervention
    Control group

    True control

Interventions

06

What researchers measure

Primary outcomes

  1. Linear growth by measuring length

    Efficacy of providing one chicken egg per day on linear growth and stunting prevalence compare to a control

    Time frame: 6 months

Secondary outcomes

  1. Motor development using Pictorial Gross Motor Milestone Chart

    Effects of consuming one chicken egg per day on motor development compare to a control

    Time frame: 6 months

  2. Biomarkers of anaemia, iron, vitamin A and essential fatty acids

    Effects of consuming one chicken egg per day on biochemical biomarkers compare to a control

    Time frame: 6 months

  3. Morbidity status

    Effects of consuming one chicken egg per day on morbidity symptoms compare to a control

    Time frame: 6 months

07

Study locations

1 site
  • Jouberton area in the Matlosana sub-district
    Klerksdorp, North West 2574, South Africa
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Dec 2023, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Dec 23, 2021
StartActual
Feb 13, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05168085
Lead sponsor
North-West University, South Africa
Responsible party
Marius Smuts (Professor, North-West University, South Africa) — Principal investigator
First posted
Dec 23, 2021
Start date
Feb 13, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 24, 2023

Study contacts

Marius Smuts, PhD
principal investigator · Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Egg as food

Start the discussion